Hong Kong
· Delayed Price · Currency is HKD ImmuneOnco Biopharmaceuticals (Shanghai) Company Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China.
The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors.
It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL.
In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors.
It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.
| Country | China |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 156 |
| CEO | Wenzhi Tian |
Contact Details
Address: Unit 15 Shanghai China | |
| Phone | 86 21 3801 6387 |
| Website | immuneonco.com |
Stock Details
| Ticker Symbol | 1541 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100006624 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wenzhi Tian | Founder, Chief Executive Officer, Chief Scientific Officer and Chairman of the Board |
| Song Li | Vice President of Research and Development and Executive Director |
| Mei Guan | Joint Company Secretary, Vice President of the Financing and Investment Strategy Department and Executive Director |
| Dr. Xiaodong Gan | Counsel |
| Dr. Zikai Xiong Ph.D. | Senior Vice President |
| Ruliang Zhang | Deputy GM, Senior Vice President and Executive Director |
| Dr. Weihai He | Chief Business Officer |
| Kin Wai Li | Joint Company Secretary |